To access this element change to forms mode OFF
Grant Award View - GA52675
N-cadherin inhibitors as vascular disrupting agents: increasing drug...
GA ID:
GA52675
Agency:
Cancer Australia
Approval Date:
20-May-2019
Publish Date:
3-Jul-2019
Category:
Cancer
Grant Term:
27-May-2019 to 26-May-2021
Value (AUD):
$66,198.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
CA 18/19 Improved cancer control
Grant Program:
2018 Priority-driven Collaborative Cancer Research Scheme
Grant Activity:
N-cadherin inhibitors as vascular disrupting agents: increasing drug delivery to tumours and improving quality of life for cancer patients
Purpose:
Peripheral neuropathy is a frequent complication of bortezomib treatment in patients with the haematological cancer multiple myeloma. This causes debilitating pain, which often necessitates stopping treatment, negatively impacting survival for these patients. The investigator will examine whether a novel drug that dramatically increases the anti-tumour effects of bortezomib can be used to increase the efficacy and decrease the toxic side-effects of bortezomib and other anti-myeloma therapies.
GO ID:
GO Title:
2018 PdCCRS Project Grants for funding commencing 2019
Internal Reference ID:
2018 PdCCRS
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
The University of Adelaide
Recipient ABN:
61 249 878 937
Grant Recipient Location
Suburb:
Adelaide
Town/City:
Adelaide
Postcode:
5000
State/Territory:
SA
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
National
Postcode:
Multiple
Country:
AUSTRALIA